Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michaela Angelika Ihle

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Cancers|June 10, 2023
Overview of Molecular Detection Technologies for Carina Heydt, Michaela Angelika Ihle, Sabine Merkelbach-Bruse
Oncotarget|March 5, 2016
Oncogene and therapeutic target analyses in atypical fibroxanthomas and pleomorphic dermal sarcomasDoris Helbig, Michaela Angelika Ihle, Katharina Pütz, et al.
Oncotarget|June 4, 2015
FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitroHelen Künstlinger, Jana Fassunke, Hans-Ulrich Schildhaus, et al.
BMC Cancer|January 14, 2014
Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutationsMichaela Angelika Ihle, Jana Fassunke, Katharina König, et al.
Plos One|August 9, 2014
Comparison of pre-analytical FFPE sample preparation methods and their impact on massively parallel sequencing in routine diagnosticsCarina Heydt, Jana Fassunke, Helen Künstlinger, et al.
Human Pathology|February 5, 2017
Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare eventsSebastian Huss, Helen Pasternack, Michaela Angelika Ihle, et al.
Molecular Oncology|April 23, 2015
miRNA-221 and miRNA-222 induce apoptosis via the KIT/AKT signalling pathway in gastrointestinal stromal tumoursMichaela Angelika Ihle, Marcel Trautmann, Helen Kuenstlinger, et al.
BMC Cancer|April 18, 2015
Massively parallel sequencing fails to detect minor resistant subclones in tissue samples prior to tyrosine kinase inhibitor therapyCarina Heydt, Niklas Kumm, Jana Fassunke, et al.
Oncotarget|January 10, 2018
Copy number variations in atypical fibroxanthomas and pleomorphic dermal sarcomasDoris Helbig, Alexander Quaas, Cornelia Mauch, et al.
BMC Cancer|May 14, 2020
Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitorsSvenja Wagener-Ryczek, Carina Heydt, Juliane Süptitz, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Cancers|June 10, 2023
Overview of Molecular Detection Technologies for Carina Heydt, Michaela Angelika Ihle, Sabine Merkelbach-Bruse
Oncotarget|March 5, 2016
Oncogene and therapeutic target analyses in atypical fibroxanthomas and pleomorphic dermal sarcomasDoris Helbig, Michaela Angelika Ihle, Katharina Pütz, et al.
Oncotarget|June 4, 2015
FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitroHelen Künstlinger, Jana Fassunke, Hans-Ulrich Schildhaus, et al.
BMC Cancer|January 14, 2014
Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutationsMichaela Angelika Ihle, Jana Fassunke, Katharina König, et al.
Plos One|August 9, 2014
Comparison of pre-analytical FFPE sample preparation methods and their impact on massively parallel sequencing in routine diagnosticsCarina Heydt, Jana Fassunke, Helen Künstlinger, et al.
Human Pathology|February 5, 2017
Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare eventsSebastian Huss, Helen Pasternack, Michaela Angelika Ihle, et al.
Molecular Oncology|April 23, 2015
miRNA-221 and miRNA-222 induce apoptosis via the KIT/AKT signalling pathway in gastrointestinal stromal tumoursMichaela Angelika Ihle, Marcel Trautmann, Helen Kuenstlinger, et al.
BMC Cancer|April 18, 2015
Massively parallel sequencing fails to detect minor resistant subclones in tissue samples prior to tyrosine kinase inhibitor therapyCarina Heydt, Niklas Kumm, Jana Fassunke, et al.
Oncotarget|January 10, 2018
Copy number variations in atypical fibroxanthomas and pleomorphic dermal sarcomasDoris Helbig, Alexander Quaas, Cornelia Mauch, et al.
BMC Cancer|May 14, 2020
Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitorsSvenja Wagener-Ryczek, Carina Heydt, Juliane Süptitz, et al.
Pageof 2